

Learn more about PADCEV® (enfortumab vedotin)

Dear {{customText[Dr|Prof|Ms|Mr|Sister|Mrs|Mdm]}} {{accFname}}
{{accLname}},

You are invited to

Patient Management Strategies for Locally Advanced/Metastatic Urothelial Cancer with Enfortumab Vedotin: A Clinical Case Discussion Lunch Talk

a meeting sponsored by Astellas to discuss PADCEV, an innovative Nectin-4-targeted treatment, developed to treat adult patients with LA/mUC who have previously received a platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor.^{1,2}

WANT TO KNOW MORE?

When?

Thursday, 22 August 2024 12:00 - 13:00

Where?

**Crystal Jade Golden Palace Paragon
Shopping Centre, #05-22 290 Orchard Road,
(S) 238859**

[Sign up here ▶](#)

Agenda

| Duration | Sessions | Speaker |
|----------|---|------------------------------------|
| 5 min | Welcome and introduction | Dr Toh Chee Keong (Chairperson) |
| 30 min | Patient Management Strategies for Locally Advanced/Metastatic Urothelial Cancer Treatment with Enfortumab Vedotin: A Clinical Case Discussion | Dr Peter O'Donnell |

20 min

Interactive Q&A

All

5 min

Summary and close

Dr Toh Chee Keong

Expert speakers



Dr Peter O'Donnell

Oncologist, University of Chicago, Medicine, USA



Dr Toh Chee Keong

Oncologist, Curie Oncology, Singapore

We look forward to seeing you there. If there are any questions or if you require additional information, please feel free to contact me using the details below.

Yours Sincerely,

{{userName}}

{{User.Phone}}

{{User.Email}}

Supported by:



CME points pending SMC approval Event ID: SSO-214

LA - locally advanced; mUC - metastatic urothelial cancer

PD-1 - programmed death-1; PD-L1 - programmed death-ligand 1

References:

1. PADCEV Singapore Approved Package Insert September 2023.
2. Powles T, Rosenberg JE, Sonpavde GP et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 2021;384(12):1125–1135.

Report any adverse events to Astellas Pharma Singapore Pte. Ltd. at pv@sg.astellas.com.

Alternatively, adverse events may be reported to the Health Sciences Authority at

Tel: 6866 1111 or online at <https://www.hsa.gov.sg/adverse-events>.

Astellas Pharma Singapore Pte. Ltd.

6 Temasek Boulevard #26-03/05 Suntec Tower Four Singapore 038986

Tel: +65-6500-9330 Fax: +65-6836-5350

www.astellas.com

Full prescribing
information is available.
Please scan here:



©2024 Astellas Pharma Singapore Pte Ltd. All rights reserved. PADCEV® and the PADCEV device are trademarks jointly by Agensys Inc., and Seagen Inc. Astellas and the flying Star logo are registered trademarks of Astellas Pharma Inc.

To unsubscribe or manage your subscription preferences, please click [here](#). For more information about your privacy rights and how we protect your personal information, please view our [privacy notice](#).

